The median recurrence-free survival from RC was 9.8 months (95% CI 7.2-12.5) in all patients (Figure 4A) and was similar between the different PD-L1 tumor cell expression (IC0: median [95% CI] RFS 10.2 months [8.9-11.4]; IC1: 4.4 [0.0-10.3] and IC2/3: 7.3 [3.6-11.1 months]; p=0.409) and immune cell groups (positive: median RFS 10.0 months [8.1-11.9] and negative: 7.8 [2.9-12.7]; p=0.759) without statistically significant differences, Figure 4B-4C. Here, CD274 is linked to neoplasm.